Visual outcome after intravitreal bevacizumab (avastin) in the treatment of diabetic macular oedema
Keywords:
Avastin; Bevacizumab; Diabetic macular edema; Intravitreal injections; Vascular endothelial growth factorAbstract
Abstract: Objective: To evaluate the visual outcome after intravitreal injection of bevacizumab (Avastin) in patients with diabetic macular edema. Materials and Methods: A prospective study was conducted in PNS Shifa Hospital from 15 March 2010 to 15 Dec 2011 in patients with diabetic macular edema who were treated with at least one intravitreal injection of bevacizumab 1.25 mg in 0.05 ml. Patients underwent Snellen’s visual acuity testing and detailed ophthalmic examination before the procedure and monthly follow-up visits for three months. Results: There were 104 eyes of 71 consecutive patients with a mean age of 61.8 years (SD 16.1). The patients received a mean of 1.39 (SD1.35) injections of bevacizumab per eye. No adverse events were observed. The mean central macular thickness at baseline was 835 micron which improved to a mean of 360 micron at 3rd month (P < 0.001). The mean baseline acuity was log MAR = 0.52(SD 0.19) and at one month log MAR =0.22 (SD 0.20); the difference was significant (P = 0.001). At last follow-up of 3 months, the mean visual acuity was log MAR = 0.20 (SD 0.19), which was significantly better than baseline (P < 0.001). Visual acuity improved in 89 eyes. Conclusion: Intravitreal bevacizumab resulted in a significant decrease in macular edema and improvement in visual acuity. The number of patients in this study was limited and the follow-up was too short to make any specific treatment recommendations, but the favorable short-term results suggest the need for further study.
References
Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999; 14: 223-32.
Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003; 26: 2653-64.
Pelzek C, Lim JI. Diabetic macular edema: review and update. Ophthalmol Clin North Am 2002; 15: 555-63.
Ozkiris A, Evereklioglu C, Oner A, Erkilic K. Pattern electro retinogram for monitoring the efficacy of intravitreal triamcinolone injection in diabetic macular edema. Doc Ophthalmol 2004; 109: 139-45.
Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology 1987; 94: 761-74.
Jonas JB, Kamppeter BA, Harder B, Vossmerbaeumer U, Sauder G, Spandau UH. Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 2006; 22: 200-7.
Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109: 920-7.
Otani T, Kishi S. A controlled study of vitrectomy for diabetic macular edema. Am J Ophthalmol 2002; 134: 214-29.
Yamamoto T, Akabane N, Takeuchi S. Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol 2001; 132: 369-77.
Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142: 961-9.
Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-9.
Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999; 293: 865-81.
Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006;142: 1054-6.
Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142: 155-8.
Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006; 26: 994-8.
Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999-1005.
A.Ozkirs. Intravitreal Bevacizumab for Primary Treatment of Diabetic Macular Oedema. Eye 2009; 23(3):616-20.
Holladay JT. Proper method for calculating average visual acuity. J Refr Surg 1997; 13: 388-91.
Ozkiris A, Erkilic K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 2005; 40: 63-8.
Jonas JB, Kreissig I, Degenring RF. Retinal complications of intravitreal injections of triamcinolone acetonide. Graefes Arch Clin Exp Ophthalmol 2004; 242: 184-5.
Cunningham Jr ET, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ et al. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-57.
Costa RA, Jorge R, Calucci D, Melo Jr LA, Cardillo JA, Scott IU. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007; 27: 141-9.
Friedlander SM, Welch RM. Vanishing disc neovascularization following intravitreal bevacizumab (avastin) injection. Arch Ophthalmol 2006; 124: 365.
Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley Jr MA. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 2006; 26: 882-8.
Ziemssen F, Grisanti S, Bartz-Schmidt KU. The international intravitreal bevacizumab safety survey. Br J Ophthalmol 2006; 90: 1440-1.
Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007; 27: 133-40.
Ziemssen F, Deuter CM, Stuebiger N, Zierhut M. Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin). Graefes Arch Clin Exp Ophthalmol 2007; 245(6): 917-8.
Mason III JO, Albert Jr MA, Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 2006; 26: 356-7
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2014 Saquib Naeem, Muhammad Waseem
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
